Business Context and Reporting Period
This Form 8-K was filed by Eyenovia, Inc. (trading symbol: EYEN) on October 13, 2020, reporting events occurring on October 9, 2020. The filing details the entry into a Material Definitive Agreement with Bausch Health Ireland Limited, a wholly-owned subsidiary of Bausch Health Companies Inc.
Key Financial Metrics and Transaction Terms
The filing does not report standard periodic financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines the financial terms of a new licensing agreement:
- Upfront Payment: $10,000,000 payable by Bausch Health within three business days of the agreement's effective date.
- Milestone Payments: Potential aggregate payments of approximately $35,000,000 contingent on regulatory and launch-based milestones.
- Royalties: Tiered royalties ranging from mid-single digit to mid-teen percentages on gross profits from sales in the United States and Canada.
- Licensed Product: The MicroPine therapeutic candidate and the Optejet microdose dispenser.
Material Changes
The primary material change is the strategic partnership granting Bausch Health exclusive rights to the MicroPine therapeutic candidate in the United States and Canada. This agreement represents a significant potential revenue stream for Eyenovia, shifting the commercialization burden for this specific asset to Bausch Health in the defined territory.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement facilitates the commercialization of Eyenovia's MicroPine candidate through a major pharmaceutical partner. A press release regarding this transaction was issued on October 12, 2020.
Risks and Contingencies:
- Termination for Convenience: Bausch Health retains the right to terminate the agreement for either country in the territory at any time upon 90 days' written notice.
- Termination for Cause: Both parties may terminate for uncured material breach (after 60 days) or bankruptcy events.
- Royalty Adjustments: Royalty obligations are subject to adjustments in the event of generic entry, negative gross profits, or patent expiration.
- Term Limit: The agreement lasts until the later of the 10th anniversary of the first commercial sale or the expiration of the last valid patent claim.
Investor Verification Checklist
- Verify the receipt of the $10,000,000 upfront payment in Eyenovia's next financial report.
- Review the specific regulatory and launch milestones required to trigger the $35,000,000 in potential payments.
- Assess the risk of early termination by Bausch Health under the "convenience" clause.
- Confirm the status of the MicroPine therapeutic candidate and Optejet device in clinical or regulatory pipelines.
- Examine the redacted portions of Exhibit 10.1 (License Agreement) for any undisclosed restrictive covenants.